Avanos Medical, Inc. (AVNS) — Fair Value Analysis
Base-case fair value (P50): $29.12 · Current price: $24.73 · Verdict: Undervalued
The Verdict on AVNS
Our Monte Carlo simulations indicate that AVANOS MEDICAL INC (AVNS) is currently undervalued. Trading at $24.73, AVNS sits comfortably below our median fair value (P50) of $29.12. This gap represents a substantial +17.7% potential based on our probabilistic analysis, which models thousands of forward-looking scenarios for the company. The undervalued verdict suggests that the market's current assessment of AVNS at $24.73 does not fully reflect its intrinsic value potential as robustly estimated by our simulation framework. This forms the core of our current investment thesis for AVNS.
How AVNS stacks up against peers
Despite its sector being unspecified, AVNS holds an average quality tier, signifying its operational and financial health compared to its industry peers. This average rating implies a balanced risk profile rather than exceptional strength or weakness. The observed +17.7% from the current trading price of $24.73 to the $29.12 fair value is noteworthy, considering AVNS's average quality tier. It suggests that even without being a top-tier performer, the company's fundamentals are robust enough to support a significant re-rating towards its $29.12 estimate, as projected by our Monte Carlo analysis.
What this means for investors
Investors analyzing AVANOS MEDICAL INC should note the compelling undervalued assessment stemming from our Monte Carlo simulations. The potential +17.7% to the median fair value of $29.12 from the current $24.73 offers a clear data point for consideration. While AVNS is an average quality tier company, the rigorous simulation process identifies a strong case for appreciation. The model's outputs suggest that a range of favorable future outcomes could lead to a significant move towards the $29.12 target. For deeper insights into the probability distribution, including detailed bear and bull scenarios, investors can sign up for FairCurve to see the full distribution and track AVNS's fair value as new fundamentals are released.
Frequently Asked Questions
Is AVNS overvalued or undervalued right now?
Based on our Monte Carlo simulations, AVANOS MEDICAL INC (AVNS) is currently undervalued. Our median fair value estimate of $29.12 is above its current trading price of $24.73.
What is the bear case and bull case for AVNS?
The full Monte Carlo distribution, including detailed bear (P10) and bull (P90) target prices, along with the probability of achieving upside scenarios, is exclusively available with a free FairCurve account.
How does FairCurve calculate AVNS's fair value?
FairCurve calculates AVNS's fair value using sophisticated Monte Carlo simulations that model thousands of forward scenarios for the company's financial performance.
How can I track AVNS's fair value as it changes?
You can add AVNS to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts whenever new earnings reports or significant fundamental data are released.